All Pancreatic ductal adenocarcinoma (PDAC) articles
-
NewsFDA approves first-in-class oral RAS inhibitor for pancreatic cancer
US authorisation illustrates how targeted therapies can reshape outcomes in cancer patients even in the most aggressive forms of the disease.
-
NewsCould personalised mRNA vaccine be first for cancer?
Half of pancreatic ductal adenocarcinoma (PDAC) patients given a personalised mRNA neoantigen vaccine experienced delayed recurrence 18 months post-vaccination.
-
NewsOnivyde® improves survival in Phase III pancreatic cancer trial
Onivyde® (irinotecan liposome injection) treatment regimen significantly improved survival in a Phase III trial compared to nab-paclitaxel plus gemcitabine.